Source: International Congress 2014 – Clinical management of interstitial lung diseases and vasculitis
Disease area: Interstitial lung diseases

Abstract

Background: Three multinational, randomised, phase 3 trials of PFD (ASCEND and CAPACITY Studies) with similar study designs and populations have been performed in patients with IPF (N Engl J Med 2014; 370:2083-92; Lancet 2011; 377:1760-9). Data through the prespecified primary endpoint assessment in each study were pooled to provide robust estimates of the pirfenidone treatment effect.Methods: Analyses included all randomized patients and all observations through Week 52 in ASCEND and Week 72 in CAPACITY, and used Cox proportional hazards model and log rank test. Outcomes included time to FVC decline ³10% or death, progression-free survival (FVC decline ³10% or 6MWD decline ³50 m or death), and 4 mortality outcomes.Results: A total of 1247 patients were analysed (PFD, N=623; placebo, N=624). PFD reduced FVC decline (hazard ratio [HR] 0.48; 95% confidence interval [CI] 0.37, 0.63), prolonged PFS (HR 0.62; 95% CI 0.52, 0.75) and reduced all-cause mortality (HR 0.63; 95% CI 0.41, 0.98). The most common adverse events were gastrointestinal and skin-related, and were generally mild to moderate in severity and infrequently led to discontinuation.Conclusions: These pooled analyses showed a favourable and persistent PFD treatment effect on FVC, PFS, and all-cause mortality through 72 weeks of follow-up. PFD was generally safe and well tolerated.



Rating:

Share or cite this content

Citations should be made in the following way:
P. W. Noble, C. Albera, W. Z. Bradford, U. Costabel, R. M. du Bois, R. S. Fishman, I. Glaspole, M. K. Glassberg, L. Lancaster, D. Lederer, J. A. Leff, S. D. Nathan, C. A. Pereira, J. J. Swigris, DO, D. Valeyre, T. E. King, Jr. (Los Angeles, Brisbane, Miami, Nashville, New York, Falls Church, Denver, San Francisco, United States Of America; Turin, Italy; Essen, Germany; London, United Kingdom; Melbourne, Australia; São Paulo, Brazil; Bobginy, France). LATE-BREAKING ABSTRACT: Pirfenidone (PFD) effect on morbidity and mortality in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2014; 44: Suppl. 58, 4501

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 LATE-BREAKING ABSTRACT: Antiacid therapy and progression free survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Biopsy documented idiopathic interstitial pneumonias - Analysis of diagnostic yield, survival and mortality over 9 years Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions Year: 2013 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016